Claim Details

View detailed information about this claim and its related sources.

Back to Claims

Claim Information

Complete details about this extracted claim.

Claim Text
The reason for the refusal was that the company had not run an “adequate and well-controlled” study but had compared its product with a flu vaccine that “does not reflect the best-available standard of care.”
Simplified Text
The reason for the refusal was that Moderna had not run an adequate and well-controlled study and compared its product with a flu vaccine that does not reflect the best-available standard of care
Confidence Score
0.900
Claim Maker
Dr. Prasad’s letter to Moderna
Context Type
News Article
Context Details
{
    "person": "Dr. Prasad",
    "reason_for_refusal": "inadequate study and comparison with a non-standard vaccine"
}
Subject Tags
Policy Health
UUID
a1164c05-75b9-4579-9d6f-0ec03b30a871
Vector Index
âś— No vector
Created
February 15, 2026 at 4:02 PM (6 months ago)
Last Updated
February 15, 2026 at 4:02 PM (6 months ago)

Original Sources for this Claim (1)

All source submissions that originally contained this claim.

Screenshot of https://nytimes.com/2026/02/10/health/fda-moderna-mrna-flu-vaccine.html
F.D.A. Rejects Moderna’s M.R.N.A. Flu Vaccine, a Sign of Policy Shift
Completed News
30 claims 🔥
1 week ago
https://nytimes.com/2026/02/10/health/fda-moderna-mrna-flu-vaccine.html

The FDA rejected Moderna's mRNA flu vaccine, signaling a shift in federal health policy under Health Secretary Robert F. Kennedy Jr. The rejection is based on concerns about the clinical trial's comparison product. Moderna's stock has plummeted since its peak.

FDA Moderna mRNA Vaccine Flu Vaccine Robert F. Kennedy Jr. Vaccine Policy Vaccine Development

Similar Claims (5)

Other claims identified as semantically similar to this one.